ECSP16096477A - COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION - Google Patents

COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION

Info

Publication number
ECSP16096477A
ECSP16096477A ECIEPI201696477A ECPI201696477A ECSP16096477A EC SP16096477 A ECSP16096477 A EC SP16096477A EC IEPI201696477 A ECIEPI201696477 A EC IEPI201696477A EC PI201696477 A ECPI201696477 A EC PI201696477A EC SP16096477 A ECSP16096477 A EC SP16096477A
Authority
EC
Ecuador
Prior art keywords
rosuvastatin
oral administration
ezetimiba
procedure
preparation
Prior art date
Application number
ECIEPI201696477A
Other languages
Spanish (es)
Inventor
Jong Soo Woo
Kyeong Soo Kim
Jae Hyun Park
Seung Jun Lee
Yong Il Kim
Ha Young Jeong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16096477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of ECSP16096477A publication Critical patent/ECSP16096477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una formulación compuesta sólida para la administración oral que incluye: una porción correspondiente a gránulos húmedos de ezetimiba que incluye ezetimiba que se granula por vía húmeda utilizando un granulador de lecho fluido; y una porción correspondiente a una mezcla de rosuvastatina que incluye rosuvastatina o una de sus sales farmacéuticamente aceptables.A solid composite formulation for oral administration is provided that includes: a wet granule portion of ezetimibe including ezetimibe that is wet granulated using a fluid bed granulator; and a portion corresponding to a mixture of rosuvastatin including rosuvastatin or a pharmaceutically acceptable salt thereof.

ECIEPI201696477A 2014-06-25 2016-12-23 COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION ECSP16096477A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (en) 2014-06-25 2014-06-25 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
ECSP16096477A true ECSP16096477A (en) 2017-01-31

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201696477A ECSP16096477A (en) 2014-06-25 2016-12-23 COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION

Country Status (10)

Country Link
KR (1) KR101977785B1 (en)
AR (1) AR100977A1 (en)
BR (1) BR112016030111A2 (en)
CL (1) CL2016003283A1 (en)
EC (1) ECSP16096477A (en)
JO (1) JOP20150154B1 (en)
SG (2) SG11201610748RA (en)
TW (1) TWI700100B (en)
UY (1) UY36190A (en)
WO (1) WO2015199356A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
CZ2016539A3 (en) * 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
KR102206535B1 (en) * 2016-11-29 2021-01-22 한미약품 주식회사 Oral composite tablet comprising ezetimibe and rosuvastatin
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR20200137243A (en) 2019-05-29 2020-12-09 콜마파마(주) Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
BR112023003323A2 (en) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION IN SINGLE DOSAGE FORM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (en) * 2007-09-05 2009-07-09 박재섭 The golf club using moving ball
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
HUE038048T2 (en) * 2009-07-28 2018-09-28 Egyt Gyogyszervegyeszeti Gyar New granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
MX365046B (en) * 2012-05-01 2019-05-17 Althera Life Sciencies Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases.

Also Published As

Publication number Publication date
TW201625223A (en) 2016-07-16
KR20160000762A (en) 2016-01-05
CL2016003283A1 (en) 2017-07-28
BR112016030111A2 (en) 2017-08-22
WO2015199356A1 (en) 2015-12-30
TWI700100B (en) 2020-08-01
JOP20150154B1 (en) 2021-08-17
KR101977785B1 (en) 2019-05-14
UY36190A (en) 2015-10-30
SG11201610748RA (en) 2017-01-27
AR100977A1 (en) 2016-11-16
SG10201811586YA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
ECSP16096477A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION
CL2016002517A1 (en) Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
CR20160191A (en) COMPOUNDS DERIVED FROM BICYCLIC PIRIDYL FUSED TO RING AS FGFR4 INHIBITORS
CL2018003569A1 (en) Fxr modulating compounds (nr1h4).
DOP2016000177A (en) DERIVATIVE COMPOUNDS AND COMPOSITIONS OF N-AZASPIROCICLOALCANO N-HETEROARIL REPLACED TO INHIBIT THE ACTIVITY OF SHP2
CR20150549A (en) HETEROCYCLIC COMPOUNDS AND THEIR USES
CR20180253A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS
UY33370A (en) Pharmaceutical compositions comprising a DPP4 and pioglitazone inhibitor drug, preparation and use procedures
EA201892415A1 (en) POLYMORPHONE FORM
DOP2014000255A (en) BICYCLICALLY REPLACED URACILES AND USE OF THE SAME
BR112017008993A2 (en) Methods and Compositions Specifically for the Treatment of Attention Deficit Disorder
CL2014001828A1 (en) Dual-release oral dosage system comprising doxylamine and pyridoxine and / or its analogs, metabolites and salts thereof; oral dosage form dual release; pharmaceutical kit; use to relieve symptoms of nausea and vomiting, including those of pregnancy.
PH12015500823A1 (en) Modified release formulations for oprozomib
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
NZ731118A (en) Dopamine d3 receptor antagonists compounds
UY36124A (en) CARBOXAMIDE DERIVATIVES
UY36123A (en) CARBOXAMIDE DERIVATIVES
AR099943A1 (en) CHRICAL DERIVATIVES OF 2,5-DISPOSED CYCLOPENTANCARBOXYL ACID AND ITS USE
CL2016000182A1 (en) Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process
BR112016015175A2 (en) PHARMACEUTICAL FORMULATION, METHOD FOR MANUFACTURING A PHARMACEUTICAL FORMULATION COMPRISING SILDENAFIL AND CLOMIPRAMINE AND TABLET
EA201991359A1 (en) PHARMACEUTICAL MEDICINAL FORMS
AR100153A1 (en) MEDICINE
CL2015003780A1 (en) Pyrimido-isoquinolin-quinone derivative compounds, their salts, isomers, acceptable pharmaceutical tautomers; farm compositions; preparation procedure; and its use in the treatment of multiresistant bacterial and bacterial diseases.
PE20170130A1 (en) (S) - PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE